Form 4: PTGX CMO Sells Shares for Tax Obligation

Protagonist Therapeutics' Chief Medical Officer, Arturo Molina, MD, sold 2,712 shares of common stock to cover tax obligations related to restricted stock unit settlement.

Summary

• Arturo Molina, MD, Chief Medical Officer of Protagonist Therapeutics, Inc. (PTGX), reported a sale of common stock.
• The transaction involved the disposition of 2,712 shares of PTGX common stock.
• The shares were sold at a price of $84.77 per share.
• The sale was executed on November 17, 2025.
• The purpose of the sale was to cover tax withholding obligations incurred upon the settlement of restricted stock units.
• Following this transaction, Arturo Molina, MD, beneficially owns 81,180 shares of Protagonist Therapeutics common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the sale is explicitly stated to be for covering tax withholding obligations upon RSU settlement, which is a common and non-discretionary event for executives receiving equity compensation, rather than a reflection of management's view on the company's future prospects.

Industry Context

This filing represents a routine insider transaction, specifically a non-discretionary sale to cover tax liabilities arising from the vesting of equity awards. Such transactions are common across all industries when executives receive restricted stock units or other forms of equity compensation.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary sale for tax purposes and does not signal a change in management's confidence or company fundamentals.

Key Dates

Keywords

Protagonist Therapeutics, PTGX, Insider Trading, Form 4, Stock Sale, Chief Medical Officer, Tax Withholding, Restricted Stock Units